Skip to main content

Table 2 Drug prescription pattern according to chronic kidney disease grade

From: Clinical benefits and risks of anticoagulation therapy according to the degree of chronic kidney disease in patients with atrial fibrillation

CKD Grade

1

2

3

4

5

p

(n = 3096)

(n = 5420)

(n = 3338)

(n = 482)

(n = 378)

 

Aspirin

1535 (49.6)

2565 (47.3)

1461 (43.8)

218 (45.2)

187 (49.5)

< 0.001

Clopidogrel

562 (18.2)

994 (18.3)

590 (17.7)

121 (25.1)

110 (29.1)

< 0.001

Beta blocker

1262 (40.8)

2182 (40.3)

1342 (40.2)

168 (34.9)

136 (36.0)

0.066

Calcium channel blocker

644 (20.8)

1233 (22.7)

731 (21.9)

101 (21.0)

81 (21.4)

0.314

Digoxin

456 (14.7)

1064 (19.6)

962 (28.8)

120 (24.9)

37 (9.8)

< 0.001

Amiodarone

603 (19.5)

989 (18.2)

707 (21.2)

139 (28.8)

116 (30.7)

< 0.001

Class Ic AAD∫

1317 (42.5)

1743 (32.2)

585 (17.5)

37 (7.7)

39 (10.3)

< 0.001

Anticoagulants

1061 (34.3)

1966 (36.3)

1224 (36.7)

134 (27.8)

62 (16.4)

 

Warfarin

871 (82.1)

1668 (84.8)

1047 (85.5)

122 (91.0)

60 (96.8)

0.002

NOAC

190 (17.9)

298 (15.2)

177 (14.5)

12 (9.0)

2 (3.2)

 

Dabigatran

Rivaroxaban

Apixaban

Edoxaban

107 (56.3)

51 (26.8)

31(16.3)

1 (0.5)

125 (41.9)

109 (36.6)

64 (21.5)

0 (0.0)

58 (32.8)

86 (48.6)

32 (18.1)

1 (0.6)

3 (25.0)

4 (33.3)

5 (41.7)

0 (0.0)

0 (0.0)

0 (0.0)

2 (100.0)

0 (0.0)

< 0.001

  1. Data are presented as a number (%)
  2. CKD: Chronic kidney disease, AAD: Antiarrhythmic drug, NOAC: Non-vitamin K oral anticoagulants